Search

Travel Grants

Travel grant application is now closed. Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.

Read more

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

CarrerasLeaders call two is now open

The second CarrerasLeaders call is open: apply now to the postdoctoral program to empower future leaders in the fight against blood cancers.

Read more

The European Parliament adopts the Regulation on Substances of Human Origins (SoHO)

On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).

Read more

EHA joins ESMO in calling for EU action on shortages of essential medicines

EHA joins ESMO in calling for EU action on shortages of essential medicines

The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

SWG Educational Activities

2023 was a brainstorming year for the SWG.

Read more

GAPP Joint Action

Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.

Read more

Second EHA-SAH tutorial in Argentina, another success

Hematologists from South America and mainland US gathered in Argentina on September 14-15 for brain-stretching exercises on the topics of lymphoid malignancies and plasma cell dyscrasias.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more